Transcription profiling by array of ER-positive breast cancer biopsies taken before and after 4 weeks of fulvestrant treatment

Analysis of breast cancer tumors following fulvestrant treatment for 4 weeks. Fulvestrant is a highly specific ER antagonist used to treat postmenopausal women with breast cancer. Data provide insight into the molecular mechanism of action of fulvestrant on whole genome expression.